Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
José Baselga(Novartis (Switzerland)), Frederico Costa(Apple (Israel)), Brigitte Van Eyll(Apple (Israel)), Hélio Pinczowski(Apple (Israel)), Sebastião Cabral Filho(Apple (Israel)), Begoña Bermejo(Hospital Clínico Universitario de Valencia), Bernardo Garicochea(Apple (Israel)), Antonio Llombart‐Cussac(MedSIR (Spain)), Sunhee Ro(Apple (Israel)), Henri Roché(Inserm), Marc Espié(Hôpital Saint-Louis), Shell Li(Apple (Israel)), Miguel Á. Climent Durán(Apple (Israel)), Andre Augusto Junior Gemeinder de Moraes(Apple (Israel)), Paulo M. Hoff(Translational Research in Oncology), Auro del Giglio(Centro de Pesquisas Oncológicas), Eva Ciruelos(Hospital Universitario 12 De Octubre), J. G. M. Segalla(Apple (Israel)), Ronaldo A. Ribeiro(Apple (Israel)), Patricia Gómez(Apple (Israel)), Clarissa Mathias(Apple (Israel)), B. Ojeda(Apple (Israel)), Miguel Gil Gil(Apple (Israel)), Josefa Morales(Apple (Israel))
Cited by 163
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k